NCT04896385 - A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

November 17, 2022

Study Completion Date

July 10, 2023

Conditions

Vitiligo

Interventions

DRUG

Ruxolitinib cream

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

DRUG

Vehicle Cream

Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

Trial Locations (13)

Mount Sinai Hospital, New York

Suny Downstate Medical Center, Brooklyn

George Washington Medical Faculty Associates, Washington D.C.

Hopital Saint Andre, Bordeaux

UC Irvine, Irvine

First Oc Dermatology, Fountain Valley

Centre Hospitalier Universitaire Henri Mondor, Créteil

Dermatology Specialists of Spokane, Spokane

Dermatology Research Institute, Calgary

Simcoderm Medical and Surgical Dermatology Center, Barrie

Lynderm Research Inc, Markham

JRB Research Inc, Ottawa

Hopital Archet 2 Derm Dept, Nice